The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity

What this article covers: Available capacity can start a conversation, but it cannot carry a complex program to market on its own. Pharma and biopharma companies also need quality, regulatory credibility, technical judgment, transparent communication, cost control, and reliable execution.

Article Abstract:

A broad service portfolio does not automatically create an integrated CDMO. The value emerges when modality-specific expertise in biologics, drug-device combinations, complex sterile injectables, and specialized oral dosage forms is supported by common operating principles and consistent execution.

In this article, Kamal Preet, Vice President and Global Head of Biologics at OneSource, examines what multi-modality should mean in practice. She explores how connected capabilities can reduce handoff risk, strengthen development and commercialization, and give clients a more coordinated path from early development through global supply.

This Article Covers:

• Why quality, regulatory credibility, cost competitiveness, and execution matter as much as capacity
• Where fragmented outsourcing can lose knowledge, time, accountability, and cost control
• How shared systems and cross-modality learning can improve program decisions and troubleshooting
• Why standardization benefits some programs while novel products require greater customization
• How OneSource connects biologics, drug-device combinations, complex sterile injectables, and soft gelatin capsules within an integrated platform